An analyst thinks he has cracked the code on why highflying Eli Lilly missed two quarters of Wall Street projections.
We recently compiled a list of the Jim Cramer Discussed These 10 Stocks, AI Power Demand & Healthcare. In this article, we ...
NEW YORK, NY / ACCESS Newswire / January 28, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...
The actor said he lost 40 pounds taking GLP-1 medication before a negative side effect necessitated a change to a different ...
Most Wall Street professionals obsess over short-term returns. However, patient individual investors who buy and hold leading stocks on the cusp of new growth trends could strike it rich.
Ozempic, the drug that was originally approved to treat type 2 diabetes, has now also been approved by the FDA to reduce ...
The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...
A multi-million dollar Super Bowl ad from telehealth company Hims and Hers downplays risks and side effects of compounded ...
Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves a gradual loss of kidney function.
Type 2 diabetes is a leading cause of chronic kidney disease, which affects more than 1 in 7 U.S. adults. The new approval ...
Novo Nordisk (NVO) said its popular diabetes drug Ozempic, also known as semaglutide, has been approved to reduce the risk of kidney disease worsening, kidney failure, and death from cardiovascular ...
The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...